Dear reader,
Anyone curious about peptides is welcome here. But this newsletter is built for women, because the peptide conversation was not.If you are on a GLP-1, considering one, eyeing the serum aisle, or just tired of hearing the word "peptide" forty times a day without a straight explanation, you are who we write for. No science background required. A preference for evidence over enthusiasm helps.
A weekly newsletter that reads the peptide and GLP-1 research so you don't have to. Each issue checks every claim against the peer-reviewed evidence and reports what actually holds up for women specifically. Every compound we name is tagged with its real regulatory category: FDA-approved drug, cosmetic or supplement, compounded medication, or research-only product. Every issue is reviewed by a licensed pharmacist before it reaches your inbox.We cover semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), BPC-157, copper peptides, and the broader class of compounds circulating through telehealth, med spas, and online markets. When new research publishes or regulators act, we cover it the same week, in plain English.
Peptide is the buzzword of the moment. GLP-1 medications made it a household word, and the internet responded with thousands of confident protocols, dosing guides, and vendor pitches. Almost none of it was built for women's bodies, and very little of it was grounded in what the trials actually found.Here is the part that gets missed: women were in the trials. The pivotal semaglutide weight-loss trial was 73 percent female. The tirzepatide trial was 68 percent female. But being included is not the same as being studied. Neither trial reported results by menstrual cycle phase. Neither analyzed outcomes by menopausal status. Periods, PCOS, pregnancy planning, perimenopause, menopause: the questions that define how these medications actually land in a woman's life mostly went unmeasured.The trials were full of women. The analysis was not designed for them. That gap is where this newsletter lives. We cover the science that exists and we name the gaps where it doesn't, because both matter.
We don't just want to hand you conclusions. We want you to be able to dissect a peptide claim yourself: to ask which regulatory door a product is behind, who was actually in the study everyone is citing, and where the science ends and the marketing begins. Every issue practices that skill on whatever the internet got excited about that week. If you want the whole framework in two minutes, start with Peptides 101, our plain-English primer.
The Big One. The week's primary topic, in depth: mechanism, trial data, what the evidence does and does not establish, and why it may land differently in a woman's body.
The Female Data Gap. One statistic showing exactly how much of the research was never designed for women.
Deinfluenced. One viral claim from the week, graded A to F against the evidence. Most grade D or F.
Ask a Clinician. One reader question, answered by our medical reviewer in plain language. Education, not a protocol.
On the Radar. Three topics coming next, so you know what's in the queue.
Every issue is reviewed by Mais, PharmD, a licensed pharmacist, before it publishes. Her name appears on the masthead of every issue, and the Ask a Clinician section is written and signed by her in her own voice. If a claim does not meet the standard she would stand behind professionally, it does not send. Medical review is not a marketing credential here. It is the editorial process.
We do not sell peptides, supplements, or any health product, and we never will. We do not publish dosing information, sourcing guidance, or protocols. We do not provide medical advice, and nothing in any issue is a recommendation for an individual reader. When a compound has no human trial data, we say so. When a regulatory status is contested or changing, we say that too.This is education. The conversation that matters is the one with your prescriber, and our job is to make sure you walk into it informed.
The editors
Pep in Her Step